These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 2411125)

  • 41. [A promising tumor marker CA 19-9 for pancreatic carcinoma: comparison with CEA and elastase 1].
    Sakahara H; Endo K; Nakajima K; Nakashima T; Ohta H; Torizuka K; Naito A; Suzuki T
    Kaku Igaku; 1985 Jan; 22(1):115-8. PubMed ID: 3858565
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Serum pancreatic enzymes in the diagnosis of carcinoma of the pancreas].
    Pezzilli R; Ventrucci M; Talarico R; Naldoni P; Cassano A; Gullo L
    G Ital Oncol; 1989; 9(1):7-13. PubMed ID: 2468605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.
    Taylor OM; Cooper EH; Benson EA; McMahon MJ
    Eur J Surg Oncol; 1992 Oct; 18(5):508-13. PubMed ID: 1426303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CEA and ferritin in chronic pancreatic disease: a comparative evaluation.
    Fabris C; Farini R; Piccoli A; Del Favero G; Panucci A; Plebani M; Pedrazzoli S; Nitti D; Naccarato R
    Hepatogastroenterology; 1985 Jun; 32(3):146-8. PubMed ID: 4018709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limits of CEA and ferritin in the diagnosis of pancreatic cancer.
    Plebani M; Fabris C; Basso D; Del Favero G; Angonese C; Leandro G; Di Mario F; Burlina A; Naccarato R
    Int J Pancreatol; 1988; 3 Suppl 1():S113-7. PubMed ID: 3209864
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma].
    Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R
    Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical evaluation of serum carbohydrate antigen 19-9 in carcinoma of the lung--a comparison with carcinoembryonic antigen].
    Hayashibe A; Kodama T; Nishiwaki Y; Kudou H; Inoue Y; Nukariya N; Kaguraoka H; Kuroki M; Takahashi K; Nishiyama Y
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):711-5. PubMed ID: 3030198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Serum levels and clinical evaluation of CA 19-9 in various diseases].
    Toyama K; Noto M; Sakaguchi T; Adachi K; Mitomi H; Okada N; Ootaka H; Nakazawa H; Hara E
    Gan No Rinsho; 1985 Mar; 31(3):293-8. PubMed ID: 2582158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Serial changes in serum CA 19-9 levels in pancreatic cancer].
    Saito K; Tajiri H; Yoshimori M; Hijikata A; Ohkura H; Nakamura K; Ozaki H
    Gan No Rinsho; 1987 Aug; 33(9):1057-60. PubMed ID: 3476762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristic behavior of serum elastase 1 in pancreatic cancer.
    Kimura T; Ito T; Sumii T; Muranaka T
    Fukuoka Igaku Zasshi; 1991 Jun; 82(6):355-61. PubMed ID: 1715838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diagnosis of pancreatic neoplasms by analysis of tumor markers and pancreatic enzymes].
    Ochi K
    Nihon Naika Gakkai Zasshi; 1992 Dec; 81(12):1951-4. PubMed ID: 1283865
    [No Abstract]   [Full Text] [Related]  

  • 55. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
    Heptner G; Domschke S; Schneider MU; Domschke W
    Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of chronic renal failure and hemodialysis on the pancreas-specific enzyme pattern in the serum].
    Stanescu A; Mayer D; Rosenthal J; Malfertheiner P
    Leber Magen Darm; 1990 Mar; 2(2):83-9. PubMed ID: 1692102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Importance of pancreatic enzymes in blood serum for diagnosis of pancreatic diseases].
    Bondar' ZA; Tuzhilin SA
    Ter Arkh; 1975; 47(12):6-11. PubMed ID: 1224329
    [No Abstract]   [Full Text] [Related]  

  • 59. [The carcinoembryonic antigen in chronic pancreatitis].
    Brailski Kh; Mendizova A; Milkov V
    Vutr Boles; 1990; 29(2):26-30. PubMed ID: 2238619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
    Safi F; Roscher R; Beger HG
    Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.